Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1258-1267

  Raina, Komal ^a   Rajamanickam, Subapriya ^a   Deep, Gagan ^a   Singh, Meenakshi ^a,b   Agarwal, Rajesh ^a,b   Agarwal, Chapla ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; DRINKING WATER; GALLIC ACID; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TREATMENT OUTCOME; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CELL CYCLE; DISEASE COURSE; DOSE RESPONSE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; CELL CYCLE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GALLIC ACID; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS;

EID: 49849088399     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2220     Document Type: Article

References (46)

1. Stewart AB, Lwaleed BA, Douglas DA, Birch BR. Current drug therapy for prostate cancer: an overview. Curr Med Chem Anti-Canc Agents 2005;5:603-12.
2. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-9.
3. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006;13:751-78.
4. Klein EA. Chemoprevention of prostate cancer. Annu Rev Med 2006;57:49-63.
5. Abdulla M, Gruber P. Role of diet modification in cancer prevention. Biofactors 2000;12:45-51.
6. Brand TC, Canby-Hagino ED, Pratap Kumar A, Ghosh R, Leach RJ, Thompson IM. Chemoprevention of prostate cancer. Hematol Oncol Clin North Am 2006;20:831-43.
7. Shukla S, Gupta S. Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 2005;53:18-32.
8. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol 2007;178:S9-13.
9. Bagchi D, Bagchi M, Stohs S, Ray SD, Sen CK, Preuss HG. Cellular protection with proanthocyanidins derived from grape seeds. Ann N Y Acad Sci 2002;957:260-70.
10. Bagchi D, Bagchi M, Stohs SJ, et al. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 2000;148:187-97.
11. Faria A, Calhau C, de Freitas V, Mateus N. Procyanidins as antioxidants and tumor cell growth modulators. J Agric Food Chem 2006;54:2392-7.
12. Hayasaka Y, Waters EJ, Cheynier V, Herderich MJ, Vidal S. Characterization of proanthocyanidins in grape seeds using electrospray mass spectrometry. Rapid Commun Mass Spectrom 2003;17:9-16.
13. Kennedy JA, Hayasaka Y, Vidal S, Waters EJ, Jones GP. Composition of grape skin proanthocyanidins at different stages of berry development. J Agric Food Chem 2001;49:5348-55.
14. Shi J, Yu J, Pohorly JE, Kakuda Y. Polyphenolics in grape seeds - biochemistry and functionality. J Med Food 2003;6:291-9.
15. Veluri R, Singh RP, Liu Z, Thompson JA, Agarwal R, Agarwal C. Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells. Carcinogenesis 2006;27:1445-53.
16. Eng ET, Ye J, Williams D, et al. Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res 2003;63:8516-22.
17. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, Agarwal C. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 2004;108:733-40.
18. Zhao J, Wang J, Chen Y, Agarwal R. Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3′-gallate as the most effective antioxidant constituent. Carcinogenesis 1999;20:1737-45.
19. 1 arrest and apoptosis. Mol Carcinog 2000;28:129-38.
20. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 2002;23:1869-76.
21. Kaur M, Agarwal R, Agarwal C. Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated-p53 activation. Mol Cancer Ther 2006;5:1265-74.
22. Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 2003;22:1302-16.
23. Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 2007;67:5976-82.
24. Kaur M, Agarwal R, Agarwal C. Gallic acid, a major active constituent of grape seed extract, induces apoptotic death via the activation of p38 MAPK pathway in human prostate carcinoma DU145 cells. 98th Annual Meeting of AACR; 2007 Apr 14-18, Los Angeles, CA. Cadmus Journal Services, Linthicum, Abstract 4967.
25. Faried A, Kurnia D, Faried LS, et al. Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int J Oncol 2007;30:605-13.
26. Fiuza SM, Gomes C, Teixeira LJ, et al. Phenolic acid derivatives with potential anticancer properties - a structure-activity relationship study. Part 1: methyl, propyl and octyl esters of caffeic and gallic acids. Bioorg Med Chem 2004;12:3581-9.
27. Gomes CA, da Cruz TG, Andrade JL, Milhazes N, Borges F, Marques MP. Anticancer activity of phenolic acids of natural or synthetic origin: a structure-activity study. J Med Chem 2003;46:5395-401.
28. Haslam E. Natural polyphenols (vegetable tannins) as drugs: possible modes of action. J Nat Prod 1996;59:205-15.
29. Murase T, Kume N, Hase T, et al. Gallates inhibit cytokine-induced nuclear translocation of NF-κB and expression of leukocyte adhesion molecules in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:1412-20.
30. Ohno T, Inoue M, Ogihara Y. Cytotoxic activity of gallic acid against liver metastasis of mastocytoma cells P-815. Anticancer Res 2001;21:3875-80.
31. Sakaguchi N, Inoue M, Isuzugawa K, Ogihara Y, Hosaka K. Cell death-inducing activity by gallic acid derivatives. Biol Pharm Bull 1999;22:471-5.
32. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Pathol 1996;24:502-4.
33. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
34. Greenberg NM, DeMayo FJ, Sheppard PC, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-9.
35. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91.
36. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
37. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
38. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003;12:933-9.
39. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
40. Bemis DL, Buttyan R. Dietary agents/supplements hit the clinic for prostate cancer chemoprevention. Discov Med 2007;7:33-8.
41. Bidoli E, Talamini R, Bosetti C, et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 2005;16:152-7.
42. Hour TC, Liang YC, Chu IS, Lin JK. Inhibition of eleven mutagens by various tea extracts, (-)epigallocatechin-3-gallate, gallic acid and caffeine. Food Chem Toxicol 1999;37:569-79.
43. Inoue M, Suzuki R, Sakaguchi N, et al. Selective induction of cell death in cancer cells by gallic acid. Biol Pharm Bull 1995;18:1526-30.
44. Serrano A, Palacios C, Roy G, et al. Derivatives of gallic acid induce apoptosis in tumoral cell lines and inhibit lymphocyte proliferation. Arch Biochem Biophys 1998;350:49-54.
45. Agarwal C, Tyagi A, Agarwal R. Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther 2006;5:3294-302.
46. Maddison LA, Huss WJ, Barrios RM, Greenberg NM. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Prostate 2004;58:335-44.